RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
RELMADA THERAPEUTICS, INC. (RLMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 4.21 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-06-30 was 60.00K shares.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-03-31 was 620.00K shares.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 5.70M shares, a 52.23% increase from fiscal 2022.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 3.74M shares, a 46.94% decline from fiscal 2021.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2021 was 7.06M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|
| 2026-06-30 | 4.21M shares 10-Q · filed 2026-08-06 | ||
| 2023-12-31 | 5.70M shares 10-K · filed 2024-03-19 | ||
| 2023-06-30 | 60.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 680.00K shares 10-Q · filed 2023-08-08 | |
| 2023-03-31 | 620.00K shares 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | 3.74M shares 10-K · filed 2024-03-19 | ||
| 2021-12-31 | 7.06M shares 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |